Treatment
Anti-CD19-CAR CMV-specific T-lymphocytes clinical trials
We’re tracking 3 recruiting studies that include Anti-CD19-CAR CMV-specific T-lymphocytes, each written for real people, not researchers, below.
Recruiting studies
- NCT05432635RecruitingPhase 1
CAR T-cell and vaccine treatment after stem cell transplant
This Phase 1 study tests a customized immune-cell treatment (CAR T-cells) plus a vaccine given after stem cell transplant for certain aggressive B-cell non-Hodgkin lymphomas. It aims to help your immune system better recognize and attack the lymphoma and to see how safe the approach is.
Duarte, CaliforniaAges 18 years+ - NCT05801913RecruitingPhase 1
Personalized immune cell therapy plus a CMV vaccine
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
Duarte, CaliforniaAges 18 years+ - NCT06735690RecruitingEarly Phase 1
Immune cells plus vaccine after stem cell transplant for leukemia
This trial is for people with high-risk acute lymphoblastic leukemia who are getting a stem cell transplant from a family donor. After transplant, you'd receive a treatment that combines specially designed immune cells (CAR T cells) that target your leukemia, plus a vaccine that helps those cells work better.
Duarte, CaliforniaAges 18 years+
What Anti-CD19-CAR CMV-specific T-lymphocytes is being studied for
Conditions with recruiting Anti-CD19-CAR CMV-specific T-lymphocytes studies.
- Recurrent B-Cell Non-Hodgkin Lymphoma
- B-Cell Non-Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma
- Mantle Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Transformed Non-Hodgkin Lymphoma
- Transformed Non-Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Acute Lymphoblastic Leukemia
Common questions
- Are there clinical trials studying Anti-CD19-CAR CMV-specific T-lymphocytes?
- Yes. Clin2 currently lists 3 recruiting studies that include Anti-CD19-CAR CMV-specific T-lymphocytes, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Anti-CD19-CAR CMV-specific T-lymphocytes trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Anti-CD19-CAR CMV-specific T-lymphocytes an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Anti-CD19-CAR CMV-specific T-lymphocytes or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.